Search

Finally, the proportion of patients documented twice with the highest antibody level at SpV2 and SpV2+/SpV3 was similar between V3- and V3+ patients (50% vs. 60%, I P i = 0-55). Vaccine, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA, coronavirus disease 2019 (COVID-19), allogeneic haematopoietic stem cell transplantation, BNT162b2, third dose Keywords: coronavirus disease 2019 (COVID-19); vaccine; allogeneic haematopoietic stem cell transplantation; BNT162b2; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA; third dose EN coronavirus disease 2019 (COVID-19) vaccine allogeneic haematopoietic stem cell transplantation BNT162b2 severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA third dose e38 e40 3 02/28/22 20220301 NES 220301 The efficacy of two doses of anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) messenger RNA (mRNA) vaccines, successfully demonstrated in healthy populations,1 is progressively reported in recipients of allogeneic haematopoietic stem cell transplant (allo-HSCT) with, surprisingly, high humoral antibody responses of ~80%.1-3 In our own experience based on an observational study of 117 allo-HSCT adult recipients, we found that 83% of them achieved a significant specific humoral response after two doses (V1 and V2) of BNT162b2 anti-SARS-CoV-2 mRNA vaccine (Pfizer BioNTech). [Extracted from the article]

All except two patients were in complete remission at the time of first vaccine, while three patients were still on therapy (revlimid I n i = 1, tafasitamab I n i = 1, chemotherapy I n i = 1). Keywords: COVID 19; vaccine; CAR-T cells; BNT162b2; SARS-CoV-2 mRNA EN COVID 19 vaccine CAR-T cells BNT162b2 SARS-CoV-2 mRNA 360 362 3 01/17/22 20220115 NES 220115 The efficacy of anti-SARS-CoV-2 messenger RNA vaccines was first demonstrated in healthy populations.1 It was later progressively reported in immunocompromised hosts, including patients with solid tumours,2 haematological malignancies, especially B-cell chronic lymphocytic leukaemia,3,4 as well as solid organ transplants.5,6 Surprisingly, the antibody response has been shown to be impressive (around 80%) only in recipients of allogeneic haematopoietic stem cells transplant.7-9 Another immunocompromised population is patients who have received chimeric antigen receptor-T (CAR T) cell therapy. Safety and antibody response after one and/or two doses of BNT162b2 Anti-SARS-CoV-2 mRNA vaccine in patients treated by CAR T cells therapy. [Extracted from the article]

Summary: The diagnosis of Waldenström Macroglobulinaemia (WM)/lymphoplasmacytic lymphoma (LPL) remains one of exclusion because other B‐cell lymphoproliferative disorders (B‐LPD), such as marginal zone lymphoma (MZL), can fulfil similar criteria, including MYD88 L265P mutation. It has been suggested that expression of the myeloid marker CD13 (also termed ANPEP) is more frequent in LPL than in other B‐LPD and has also been described on normal and malignant plasma cells. Here, CD13 expression was tested in a cohort of 1037 B‐LPD patients from 3 centres by flow cytometry. The percentage of CD13‐expressing cells was found to be variable among B‐LPD but significantly higher in WM/LPL (median 31% vs. 0% in non‐WM/LPL, P < 0·001). In multivariate linear regression, CD13 expression remained significantly associated with a diagnosis of WM/LPL (P < 0·001). A cut‐off value of 2% of CD19+ cells co‐expressing CD13 yielded the best diagnostic performance for WM/LPL assertion. This was further improved by association with the presence or absence of IgM paraprotein. Finally, given that previously published transcriptomic data revealed no difference in CD13 (also termed ANPEP) mRNA between normal and pathological B‐cells, the hypothesis of some post‐transcriptional regulation must be favoured. These results suggest that testing for CD13 expression in routine flow cytometry panels could help to discriminate WM/LPL from other B‐LPD. [ABSTRACT FROM AUTHOR]